SLE decreases risk for hormonal cancers. by Deborah K. Johnson (10001156)

“…An OR to the left of the solid line represents a reduction in risk. (a) Breast cancer incidence in female SLE cohort is significantly decreased by SLE status (OR 0.52, 95% CI 0.35, 0.74, p = 0.0036). …”

ROS and superoxide decrease in the dormant form of mycobacteria. by Amar Yeware (7115063)

Mitochondrial protein acetylation correlates with a decrease in sirtuin 3 levels. by Mercedes García-Roche (6459200)

Downregulation of DOM decreases the abundance of PER and TIM. by Zhenxing Liu (399809)

“…Downregulation of DOM decreased PER levels at CT1-5 and CT17-21. (Scale bar: 50 um.) …”

Decrease of autoantibody levels in highly inflammatory NSG mice. by Henrika Jodeleit (4722312)

KL perception mutants exhibit decreased epidermal cell lengths and root diameter. by José Antonio Villaécija-Aguilar (7326242)

Impaired Ubr5 function results in increased canonical and decreased non-canonical HH signalling. by David Mellis (2833469)

Kinematic analyses including finite helical axes of drop jump landings demonstrate decreased knee control long after anterior cruciate ligament injury - Fig 4 by Helena Grip (7610468)

pDNA-PK levels are decreased in absence of cGAS. by Elona Gusho (4688170)

SRC-3 treatment decreased tumor growth in a Jeko-1 ibrutinib resistant mouse model. by Imani Bijou (18275174)

The conduction velocity for a cell distance of 4 <i>μ</i>m is nearly constant as the magnitude of the extracellular potential decreases. by Karoline Horgmo Jæger (6785450)

Mitochondrial function decreases in pasture-fed dairy cows during early lactation. by Mercedes García-Roche (6459200)

AMPs are increased in lesional HS, but DCD and other sweat-gland associated proteins are decreased. by Margaret Coates (6058580)

“…<p>(A) Volcano plot showing increased or decreased genes in HS. …”

AIM-100 reduces dsRNA silencing in body wall muscle and decreases DA neurodegeneration. by Anthony L. Gaeta (13272609)

Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

50 WT 5′ and 3′ terminal nts of the S1 gene are sufficient to package a non-MRV gene into infectious virions. by Debarpan Dhar (724473)

Additional file 5 of Decreased complement 4 and interleukin-10 as biomarkers in aqueous humour for non-exudative age-related macular degeneration: a case control study by Juliane Schikora (20871169)

Tax expression is associated with decreased cellular motility. by Saumya Ramanayake (7879091)

Combined illusion score index across conditions (NI: Non-Illusion; NIT: Non-Illusion Tactile; MS: Multisensory; UV: Unimodal Visual). by Kirralise J. Hansford (20670869)

Entropy score decreases over maturation in non-CM tissue contexts. by Suraj Kannan (10812701)